CJC-1295 Half-Life and Pharmacokinetics: What Research Shows (2026)

Direct answer: Peer reviewed research characterizes CJC-1295 as a long acting analog of growth hormone releasing hormone (GHRH) that produced prolonged stimulation of growth hormone and insulin-like growth factor I secretion in healthy adults (PubMed PMID 16352683). The sources cited on this page do not establish a validated human half-life value, a clearance rate, or a detection window, and published research does not establish human-use guidance of any kind, including any schedule. The compound is sold for laboratory research use only.

This page reviews what the published literature does and does not report about the pharmacokinetics of CJC-1295, how analytical laboratories detect the peptide in biological matrices, and how storage and stability are treated as research variables rather than as handling advice. All compounds discussed on this page are sold for laboratory research use only and are not for human consumption. Real Peptides supplies research-use-only compounds and publishes lot certificates of analysis at /coas/.

What does the published literature actually establish about CJC-1295 pharmacokinetics?

The peer reviewed record on CJC-1295 is small, and most of it is weighted toward what the molecule does to measurable endocrine markers rather than toward how the molecule itself moves through and out of a biological system. The most frequently cited human work is a 2006 study in the Journal of Clinical Endocrinology and Metabolism reporting prolonged stimulation of growth hormone and insulin-like growth factor I secretion by CJC-1295, described in the title as a long acting analog of GHRH, in healthy adults (PubMed PMID 16352683). A companion 2006 report in the same journal examined whether pulsatile growth hormone secretion persists during continuous stimulation by the analog (PubMed PMID 17018654). A 2009 paper in Growth Hormone and IGF Research reported that activation of the GH/IGF-1 axis by CJC-1295 produced serum protein profile changes in normal adult subjects (PubMed PMID 19386527).

What these three reports share is an endpoint structure built around circulating hormone and protein markers. They tell a reader that the compound is characterized in the literature as long acting and that downstream markers remained elevated or altered over extended windows. They are not, in the form cited here, a complete pharmacokinetic dataset with a reported terminal half-life, volume of distribution, systemic clearance, or absolute bioavailability figure that can be quoted as a number. Anyone searching for a single authoritative half-life value for CJC-1295 should understand that the commonly repeated figures circulating on forums and vendor pages are not traceable to the sources listed at the end of this page.

What is the difference between pharmacokinetics and pharmacodynamics here, and why does it matter?

Pharmacokinetics describes what a biological system does to a compound: absorption into circulation, distribution across tissue compartments, metabolism, and elimination. The standard reported parameters are maximum concentration, time to maximum concentration, area under the concentration versus time curve, terminal elimination half-life, apparent clearance, and apparent volume of distribution. Pharmacodynamics describes the reverse relationship, meaning what the compound does to measurable biology, which for a GHRH analog means growth hormone output, IGF-I concentration, and downstream protein markers.

The distinction matters because the two can diverge sharply. A peptide can be cleared from plasma long before its biological signal fades, because the receptor-level event it triggers sets off a cascade with its own kinetics. Conversely, a molecule can persist in circulation in a bound and inactive form. When the literature on CJC-1295 reports prolonged stimulation of growth hormone and IGF-I secretion (PubMed PMID 16352683), that is a statement about the duration of a pharmacodynamic signal. It is not interchangeable with a plasma half-life figure for the parent peptide, even though the two are often conflated in secondary writing. Research groups designing new work on this molecule generally need both axes measured in the same subjects, with a validated bioanalytical assay for the peptide running alongside the hormone assays.

Why is CJC-1295 described in the literature as long acting?

The phrase long acting appears directly in the titles of the primary CJC-1295 papers, including the healthy adult study (PubMed PMID 16352683), the pulsatility study (PubMed PMID 17018654), and the GHRH knockout mouse study (PubMed PMID 16822960). The structural rationale usually given in review literature is a drug affinity complex moiety designed to form a covalent link with circulating albumin, which in principle shields the peptide from rapid renal filtration and enzymatic breakdown. That is a mechanistic explanation drawn from peptide chemistry, and it should be labeled as such rather than presented as a measured value from the cited studies.

Native GHRH and truncated GHRH fragments are short peptides that are rapidly degraded by circulating peptidases, which is the problem the long acting design was intended to address. The research question that follows, and the one the 2006 pulsatility study took up, is whether extending the stimulus duration changes the character of the endocrine output rather than simply its magnitude (PubMed PMID 17018654). That is a pharmacodynamic question with pharmacokinetic roots, and it is the clearest illustration of why half-life is not a trivia figure in this field but a determinant of the entire experimental design.

What did the human studies in healthy adults report?

Three human papers anchor the public record. The 2006 Journal of Clinical Endocrinology and Metabolism study examined prolonged stimulation of growth hormone and IGF-I secretion in healthy adults (PubMed PMID 16352683). The second 2006 paper in the same journal asked whether pulsatile secretion of growth hormone persists during continuous stimulation by the analog, a question that bears directly on whether a long acting GHRH signal overrides or coexists with endogenous hypothalamic rhythm (PubMed PMID 17018654). The 2009 Growth Hormone and IGF Research paper looked downstream again, reporting serum protein profile changes in normal adult subjects following activation of the GH/IGF-1 axis (PubMed PMID 19386527).

Taken together, these describe a compound studied in a small number of controlled settings in healthy volunteers, with endpoints centered on endocrine signaling and circulating protein markers. They do not constitute an approval-grade clinical program, they do not address long term outcomes, and they do not provide the comparative data that would be needed to characterize different structural variants against each other. A 2026 review in Frontiers in Endocrinology framed exactly this problem for the broader class of GH/IGF-1 axis modulating peptides, describing a gap between clinical evidence and use outside clinical supervision (PubMed PMID 42395176).

What do animal and preclinical models contribute to the kinetic picture?

Preclinical work provides the mechanistic scaffolding that human studies of this size cannot. A 2006 paper in the American Journal of Physiology Endocrinology and Metabolism reported that once-daily exposure to CJC-1295 normalized growth in the GHRH knockout mouse, a model in which endogenous GHRH signaling is absent (PubMed PMID 16822960). That design is informative because it isolates the exogenous analog as the sole GHRH-like input, removing the confound of native pulse activity.

Equine work adds a different kind of value. A 2019 paper in Drug Testing and Analysis described a method for confirming CJC-1295 abuse in equine plasma samples by liquid chromatography tandem mass spectrometry (PubMed PMID 30938069). Analytical confirmation methods of this type are built on the ability to recover and identify the intact peptide or a characteristic fragment from a complex biological matrix, which makes them the practical foundation for any future kinetic sampling study in that species.

The caution that applies to all cross-species extrapolation applies with particular force to albumin-binding peptides. Albumin concentration, albumin sequence, peptidase activity, and renal handling all differ between species, and each of those differences can shift an elimination curve. A figure derived from one species cannot be treated as a prediction for another without direct measurement.

How do the DAC and non-DAC forms compare in the cited literature?

The name CJC-1295 is used in circulation for at least two structurally distinct materials: the analog bearing the drug affinity complex moiety, and a truncated GHRH fragment widely referred to as modified GRF 1-29, sometimes labeled CJC-1295 without DAC. The table below sets out what the sources cited on this page support for each, and, importantly, what they do not. Blank support is recorded as not established rather than filled with a figure from secondary writing.

The honest reading of that table is that the structural distinction between the two materials is chemically real and widely discussed, but the comparative pharmacokinetic evidence that would quantify it is absent from the verified source set. Background on the molecule and its development is covered separately at /cjc-1295-history/ and /cjc-1295-no-dac-faq/.

How do laboratories detect and quantify CJC-1295 in biological samples?

Detection of a GHRH analog in plasma is a hard analytical problem. The peptide is present at low concentration against a background of abundant endogenous proteins, it shares sequence homology with native GHRH, and albumin binding can complicate recovery. Two of the cited sources map the general approach.

The first is enrichment. A 2012 paper in Methods described immunoaffinity purification of peptide hormones prior to liquid chromatography mass spectrometry in doping controls (PubMed PMID 21871962). Immunoaffinity capture uses antibodies immobilized on a solid support to selectively bind the target analyte while the bulk of the matrix is washed away, which raises the effective concentration delivered to the instrument and reduces ion suppression.

The second is confirmation. The 2019 Drug Testing and Analysis method for equine plasma used liquid chromatography tandem mass spectrometry to confirm CJC-1295 (PubMed PMID 30938069). In a tandem mass spectrometry workflow, the precursor ion is isolated, fragmented, and identified by characteristic product ions, with retention time and transition ratios serving as identity criteria. Confirmation methods of this type are what allow an analyst to say that a specific peptide, rather than a structurally similar one, is present.

For a kinetic study, the same assay chemistry becomes the measuring instrument. Serial sampling, stable isotope labeled internal standards, matrix-matched calibration curves, assessment of analyte stability in the collected sample, and documented limits of detection and quantification are the elements that turn a qualitative confirmation method into a quantitative pharmacokinetic tool. The cited sources establish that the confirmation chemistry exists; they do not, in themselves, report human concentration versus time curves.

What does the doping control and surveillance literature report?

A substantial share of the published attention on CJC-1295 comes from sports science and forensic surveillance rather than from endocrinology. A 2016 paper in Forensic Science International examined how intelligence about the doping market can be produced from internet forums (PubMed PMID 27710891), and a 2016 paper in Substance Use and Misuse presented a netnography of female use of the synthetic growth hormone CJC-1295 (PubMed PMID 26771670). A 2026 critical review in the Journal of Sports Medicine and Physical Fitness assessed the use of peptide and peptide-analog drugs in recreational and professional sport and bodybuilding (PubMed PMID 41880199).

This body of work is valuable for a specific and limited purpose: it documents the circulation of the compound in non-clinical settings and the discourse that surrounds it. It is not pharmacokinetic evidence. Observational and netnographic sources record what people say and do, not what measured plasma concentrations were, and the figures quoted inside online communities have no analytical provenance. Anyone building a literature review on half-life should keep surveillance sources in a separate category from measured bioanalytical data. Related context on the broader class is collected at /cjc-1295-news-2026/.

What does the literature not establish about half-life, clearance and detection?

This is the section that matters most for a reader arriving with a numerical question. Based on the verified sources cited here, the following are not established:

• A validated human terminal elimination half-life value for CJC-1295 in either structural form. The descriptor long acting appears in study titles (PubMed PMID 16352683); a specific number does not follow from that descriptor.
• Systemic clearance, apparent volume of distribution, area under the curve, or time to maximum concentration in humans.
• A defined detection window in human matrices. A confirmation method in equine plasma is published (PubMed PMID 30938069), which is a different claim from an established human window.
• Head to head comparative pharmacokinetics between the DAC bearing analog and truncated GHRH analogs.
• Any human-use guidance, schedule, or regimen. Published research does not establish these, and nothing on this page should be read as supplying them.
• Long term safety outcomes. Several 2026 reviews describe the evidence base for unapproved peptides used in musculoskeletal and athletic contexts as incomplete, including a Sports Medicine review on approved and unapproved peptide therapies (PubMed PMID 41966639) and an American Journal of Sports Medicine review of peptide supplements in sports medicine (PubMed PMID 42578445).

That list is not an argument that the molecule is uncharacterized. It is an argument that the characterization that exists is pharmacodynamic and preclinical in emphasis, and that the specific numbers most often requested are absent from the primary record. Further Q and A on the compound is collected at /cjc-1295-faq/ and /cjc-1295-half-life/.

How do storage and stability factor into pharmacokinetic research?

Stability is a pharmacokinetic variable disguised as a housekeeping topic. If a peptide degrades in the container, in the collected sample, or on the surfaces of the labware between collection and analysis, every downstream concentration figure is wrong in a direction that is difficult to detect. Laboratories treat this as part of method validation rather than as an afterthought.

The variables typically documented in peptide bioanalysis are temperature history, light exposure, the number of freeze and thaw cycles a sample has seen, the time a sample spent at ambient temperature before processing, container material and the potential for peptide adsorption onto surfaces, and the physical state of the material, since lyophilized powder and material held in solution have different stability profiles. Analytical groups record these as metadata attached to every sample, because a reviewer cannot interpret a concentration value without them.

For laboratory stock material, the same logic applies in reverse: a compound whose identity and content are documented on a lot certificate of analysis gives a research group a defensible starting point for any kinetic calculation. Real Peptides publishes lot certificates of analysis at /coas/, and guidance on interpreting those documents is available at /how-to-read-a-coa-for-peptides/. General handling and cold chain practice is covered at /peptide-storage-guide-best-practices/ and compound-specific notes at /cjc-1295-storage/. What the regulatory label means in practice is explained at /research-use-only-meaning/.

How do the 2026 reviews frame the evidence base for GH axis peptides?

A cluster of 2026 review articles has revisited this class of compounds across several clinical specialties, and the framing is consistent. A Frontiers in Endocrinology review described the emerging landscape of performance enhancing peptides modulating the GH-IGF1 axis and explicitly positioned itself as bridging the gap between clinical evidence and use outside clinical settings (PubMed PMID 42395176). A critical review in the Journal of Sports Medicine and Physical Fitness covered peptide and peptide-analog drugs in recreational and professional sport and bodybuilding (PubMed PMID 41880199).

Orthopaedic and sports medicine literature has taken up the same material. A review in the Journal of the American Academy of Orthopaedic Surgeons Global Research and Reviews addressed applications, challenges and future directions for therapeutic peptides in orthopaedics (PubMed PMID 41490200), and a primer for orthopaedic and sports medicine physicians appeared in the American Journal of Sports Medicine (PubMed PMID 41476424). Safety and efficacy of approved and unapproved peptide therapies for musculoskeletal injuries and athletic performance was reviewed in Sports Medicine (PubMed PMID 41966639), and peptide supplements in sports medicine in the American Journal of Sports Medicine (PubMed PMID 42578445). Broader endocrine and metabolic framing appears in the International Journal of Molecular Sciences (PubMed PMID 42123471), and an aging-focused review appeared in Frontiers in Aging (PubMed PMID 42021992).

The common thread across these is that interest has outpaced controlled data, and that reviewers repeatedly distinguish between approved agents with full pharmacokinetic dossiers and unapproved research compounds without them. CJC-1295 sits firmly in the second category.

What would a well designed pharmacokinetic study of CJC-1295 need to include?

For researchers planning work rather than reading about it, the gaps identified above translate into a design checklist. A study capable of filling them would need a fully validated bioanalytical assay for the intact analyte in the chosen matrix, built on the kind of immunoaffinity enrichment and tandem mass spectrometry chemistry described in the doping control literature (PubMed PMID 21871962, PubMed PMID 30938069). It would need serial sampling dense enough to capture both the distribution and terminal phases, with the sampling window extended far enough to characterize a long acting molecule rather than truncating the curve prematurely.

It would need explicit handling of protein binding, since an albumin-associated peptide requires a decision about whether total or unbound concentration is being reported. It would need paired pharmacodynamic sampling, because the relationship between peptide concentration and growth hormone or IGF-I output is the scientifically interesting part and the two 2006 studies suggest that relationship is not simple (PubMed PMID 16352683, PubMed PMID 17018654). It would need documented sample stability data to support the concentration values reported. And it would need transparent reporting of the structural identity of the material studied, since the naming ambiguity between DAC bearing and truncated analogs is one of the main reasons the existing literature is hard to synthesize.

How was this page researched?

This page was assembled from published literature only. Every factual statement about study findings is tied to a specific PubMed-indexed record, and each source is described only as far as its published title and journal of record support. Where a commonly repeated figure, such as a specific half-life in hours or days, could not be traced to one of the verified sources, that figure was omitted rather than paraphrased from secondary writing. No internal data, customer reports, observational claims, or unpublished measurements were used. Mechanistic explanations, such as the albumin binding rationale for extended circulation, are labeled as mechanistic reasoning from peptide chemistry and not presented as measured outcomes of the cited studies. Statements beginning not established mean not established within this verified source set, which is a narrower claim than not established anywhere in the scientific record.

Source list: PubMed PMID 16352683, PubMed PMID 16822960, PubMed PMID 17018654, PubMed PMID 19386527, PubMed PMID 21871962, PubMed PMID 26771670, PubMed PMID 27710891, PubMed PMID 30938069, PubMed PMID 41476424, PubMed PMID 41490200, PubMed PMID 41880199, PubMed PMID 41966639, PubMed PMID 42021992, PubMed PMID 42123471, PubMed PMID 42395176, PubMed PMID 42578445.

Additional compound overviews are available at /cjc-1295/, /cjc-1295-vs-ipamorelin/ and /cjc-1295-vs-ghrp-2/.

Frequently asked questions

What is the published half-life of CJC-1295?

No validated human terminal half-life value for CJC-1295 appears in the verified sources cited on this page. The primary studies describe the molecule as a long acting GHRH analog in their titles and report prolonged stimulation of growth hormone and IGF-I secretion in healthy adults (PubMed PMID 16352683), which is a pharmacodynamic observation rather than a measured elimination constant. Figures circulating on forums and vendor pages are not traceable to these records.

Does prolonged hormone elevation mean the peptide is still in circulation?

Not necessarily. Pharmacodynamic duration and plasma persistence are separate measurements. A compound can be cleared while the downstream endocrine cascade it triggered continues, and it can also persist in a protein-bound state. The 2006 human report measured growth hormone and IGF-I secretion over an extended window (PubMed PMID 16352683); linking that to a parent peptide concentration curve requires a separate bioanalytical assay.

How is CJC-1295 detected in biological samples?

Published analytical work relies on mass spectrometry. A 2019 method confirmed CJC-1295 in equine plasma by liquid chromatography tandem mass spectrometry (PubMed PMID 30938069), and immunoaffinity purification of peptide hormones ahead of liquid chromatography mass spectrometry has been described for doping control workflows (PubMed PMID 21871962). Enrichment reduces matrix interference, and tandem mass spectrometry provides identity confirmation through characteristic fragment ions.

Did research examine whether a continuous GHRH signal eliminates natural growth hormone pulses?

Yes, that was the specific question of a 2006 Journal of Clinical Endocrinology and Metabolism study, which examined whether pulsatile secretion of growth hormone persists during continuous stimulation by CJC-1295 (PubMed PMID 17018654). The design is relevant to kinetics because it tests how the duration of an exogenous stimulus interacts with endogenous rhythm.

What preclinical pharmacokinetic or growth data exist?

A 2006 study in the American Journal of Physiology Endocrinology and Metabolism reported that CJC-1295 normalized growth in the GHRH knockout mouse (PubMed PMID 16822960). The equine confirmation method adds analytical capability in a second species (PubMed PMID 30938069). Species differences in albumin, peptidase activity and renal handling limit direct extrapolation of any kinetic figure between species.

Why do reviews describe the evidence base as incomplete?

Several 2026 reviews across sports medicine, orthopaedics, endocrinology and aging describe a gap between enthusiasm for GH axis peptides and the controlled data available, including reviews in Sports Medicine (PubMed PMID 41966639), Frontiers in Endocrinology (PubMed PMID 42395176) and the Journal of Sports Medicine and Physical Fitness (PubMed PMID 41880199). Unapproved research compounds generally lack the full pharmacokinetic dossier required of approved agents.

Why do surveillance and forum studies appear in a pharmacokinetics discussion?

Because they explain where unsourced numbers originate. Research on producing intelligence from internet forums (PubMed PMID 27710891) and a netnography of online discussion of CJC-1295 (PubMed PMID 26771670) document discourse in non-clinical communities. They are sociological evidence, not analytical measurement, and should be kept in a separate category from bioanalytical data.

How does storage affect pharmacokinetic measurement?

Stability is part of assay validation. Temperature history, light exposure, freeze and thaw cycles, time at ambient conditions before processing, container surface adsorption, and whether material is lyophilized or in solution all influence measured concentrations. Laboratories record these as metadata. General handling practice is covered at /peptide-storage-guide-best-practices/ and lot certificates of analysis are published at /coas/.

Does this page provide any human-use guidance?

No. Published research does not establish human-use guidance of any kind, including any schedule, and none is provided here. All compounds discussed are supplied for laboratory research use only. The meaning of that designation is explained at /research-use-only-meaning/.